$PODD

INSULET CORP (PODD) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Adoption of Nonqualified Deferred Compensation Plan On September 14, 2026, the Talent and Compensation Committee (the "Comm

ResMed (RMD) and peers reported Q2 earnings, with revenues beating estimates by 1.4% but next quarter's guidance below. RMD's revenue grew 8.6% YoY, meeting expectations, while iRhythm (IRTC) saw 20.1% growth, exceeding estimates. Insulet (PODD) and DexCom (DXCM) also reported, with mixed results. Stocks have declined since earnings, with RMD down 2.3% and IRTC down 13%.

INSULET CORP (PODD) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 3, 2026, Timothy J. Scannell, a member of the Board of Directors (the "Board") of Insulet Corporation (the "Co

Insulet PODD reports strong growth in Omnipod 5 AID system adoption, with Q2 2026 revenues up 23.8%. The company faces competition and macroeconomic pressures but has raised international growth guidance. PODD's earnings beat estimates for four straight quarters, with a 22.2% long-term growth rate. Management expects continued expansion and product development, including Omnipod 6 and a Type 2 system launch in 2027.

Insulet (PODD) reported Q2 revenue of $801.7M, up 23.5% YoY, beating estimates by 1.9% but missing next quarter's guidance. Peers iRhythm (IRTC), ResMed (RMD), and DexCom (DXCM) also reported earnings, with mixed market reactions. PODD is down 11.6% since reporting, while DXCM is up 20.6%.

iRhythm (IRTC) reported Q2 revenue of $224.2M, up 20.1% YoY, beating estimates. ResMed (RMD) reported $1.46B in revenue, up 8.6% YoY, in line with expectations. Insulet (PODD) reported $801.7M in revenue, up 23.5% YoY, beating estimates but missing guidance. IRTC stock is down 4.4%, RMD up 3.4%, and PODD down 11.6% since reporting.

Insulet (PODD) faces class action lawsuits alleging false statements about manufacturing controls and safety risks in its insulin delivery products. The lawsuits, filed by Robbins Geller and Rosen Law Firm, cover shares bought between February 2025 and May 2026. Insulet maintains revenue growth guidance of 21-23% for 2026 despite recent recalls affecting 7 million units. Analysts project varying revenue and earnings estimates for 2029, with growth potential but increased risks due to manufacturi

Analysts' consensus for Insulet (PODD) is 'Moderate Buy' with 13 'Strong Buy' ratings, 2 'Moderate Buy', 11 'Hold', and 1 'Strong Sell'. Citigroup analyst Joanne Wuensch maintained a 'Hold' rating with a $150 price target, a 3.1% upside. The mean price target is $172.46, an 18.6% premium, while the highest target is $275, an 89.1% upside.

Insider trading activity reported for US public companies includes significant purchases and sales. ADAR1 Capital bought 1.03M Tenax Therapeutics (TENX) shares for $1.81M. Kenneth Courtis acquired 15K Alpha Metallurgical (AMR) shares for $3.16M. Rex Geveden bought 5K TTM Technologies (TTMI) shares for $524.5K. Ashley McEvoy, CEO of Insulet (PODD), purchased 1.1K shares for $162.2K. Notable sales include James Wirth selling IHT shares for $1.82B, Alexander Karp selling 492K Palantir (PLTR) shares

Insulet CEO Ashley McEvoy purchased $160,000 in shares following a 55% stock decline. The company, with a $10.3B market cap and $3.1B TTM revenue, reported 23% sales growth in its latest quarter. McEvoy's purchase is seen as a bullish signal, as insider buying often predicts higher share prices. The company aims to improve user retention for its Omnipod platform and expects 21% revenue growth for the fiscal year.